1Department of Oral & Maxillofacial Pathology, School of Dentistry, Babol University of Medical Sciences, Babol, Iran.
2Dental Research Centre, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
3Health Research Institute, Babol University of Medical Science, Mazandaran, Iran.
Introduction: Natural killer (NK) cells, of which CD56 is a specific marker, play an important role in host defense against tumors. Cancer stem cells, of which aldehyde dehydrogenase isoform 1 (ALDH1) is an immunohistochemical marker, are a group of tumorigenic cells which are involved in migration and tumor recurrences. We aimed to evaluate the expression of ALDH1 and CD56 in common salivary gland tumors, as well as their relationship with each other and with a number of clinicopathologic factors.
Materials and Methods: Forty-five paraffin blocks of salivary gland tumors (pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma, 15 samples each) were selected. Malignant tumors were classified into two groups: low-grade (including mucoepidermoid carcinoma grade I) and high-grade (including mucoepidermoid carcinoma grade III and adenoid cystic carcinoma). Immunohistochemical staining for ALDH1 and CD56 markers was performed. Data were analyzed using SPSS (20) and the Chi-square test.
Results: CD56 expression was significantly higher in benign and high-grade malignant tumors (P=0.01). ALDH1 overexpressed in all three salivary tumors, but not to statistically significant degree (P=0.54). There was no statistically significant correlation between ALDH1 and CD56 expression with demographic factors (age, gender, or location of tumor; P>0.05).
Conclusion: It appears that the number of NK cells and their function change in different types of salivary gland tumors (benign/malignant) and stroma. NK cells are important components of the anti-tumor system; therefore immune dysfunction is associated with tumor progression in tumors of the salivary gland. ALDH1 overexpression suggests its role in tumorogenesis, but ALDH1 is not involved in the morphogenesis of salivary gland tumors.
Takeshi N, et al. Immunohistochemical Analysis of Salivary Gland Tumors: Application for Surgical Pathology Practice. Acta Histochem Cytochem, 2012; 45(5): 269–82.
2. Neville BW, Dam DD, Allen CM, Bouquot JE. Oral and maxillofacial pathology. 4th ed. Philadelphia: Wb saunders; 2016: 422-72.
3. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cellular & Molecular Immunology 2013;10(3): 230-52.
4. Levy E, Roberti M, Mordoh J. Natural Killer Cells in Human Cancer From Biological Functions to Clinical Applications. Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 676198, 11 pages, 2011. doi:10.1155/2011/676198
5. Miller J. Therapeutic applications: natural killer cells in the clinic. American Society of Hematology, 2013; 2013(1): 247-53.
6. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007; 1(5):555-67.
7. Kumar V, Abbas A, Aster J. Robbins Basic Pathology; 2012: Chapter 5, 161-214.
8. Wang Y, Zhe H, Gao P, Zhang N, Li G, Qin J. Cancer stem cell marker ALDH1 expression is associated with lymph node metastasis and poor survival in esophageal squamous cell carcinoma: a study from high incidence area of northern China. Dis Esophaqus, 2012; 25(6):560-5.
9. Michifuri Y, Hirohashi Y, Torigoe T, Miyazaki A, Kobayashi J, Sasaki T et al. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis. Int Pathology 2012; 62(10): 684-9.
10. Brandwein MS, Ferlito A, Bradley PJ, Hille JJ, Rinaldo A. Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 2002; 122(7): 758–64.
12. Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract, 2009; 205(5): 303-9.
13. Yan Q, Tianjie P, Li L, Fei C, Changli L, Linyong S, et al. The Expression of Aldehyde Dehydrogenase Family in Breast Cancer. J Breast Cancer 2014; 17(1): 54–60.
14. Nakatsuka S, Harada H, Fujiyama H, Takeda K, Kitamura K, Kimura H, et al. An invasive adenocarcinoma of the accessory parotid gland: a rare example developing from a low-grade cribriform cystadenocarcinoma. Diagnostic Pathology 2011; 6:122.
15. Weissferdt A, Moran C. Pulmonary salivary gland-type tumors with features of malignant mixed tumor (carcinoma ex pleomorphic adenoma): a clinicopathologic study of five cases. Am J Clin Pathol, 2011; 136(5): 793-8.
16. Dutsch M, Lazar A, Tomaszewska R. The Potential Role of MT and Vimentin Immunoreactivity in the Remodeling of the Microenvironment of Parotid Adenocarcinoma. Cancer Microenviron 2010; 4(1):105–13.
17. Wachter D, Hartmann A, Beckmann M, Fasching P, Hein A, Bayer C, et al. Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma. BioMed Research International, vol. 2014, Article ID 408459, 9 pages, 2014. doi:10.1155/2014/408459
18. Kontogianni K, Nicholson A, Butcher D, Sheppard M. CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artifact. J Clin Pathol 2005; 58(9): 978–80.
19. Alegretti A, Bittar C, Bittencourt R, Piccoli A, Schneider L, Silla L, et al. The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. Rev Bras Hematol Hemoter 2011; 33(3): 202-6.
20. Aloysius MM, Zaitoun AM, Awad S, Ilyas M, Rowlands BJ, Lobo DN. Mucins and CD56 as markers of tumour invasion and prognosis in periampullary cancer. Br J Surg 2010; 97(8): 1269–78.
21. Mamessier E, Sylvain A, Thibult M, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity. The Journal of Clinical Investigation 2011; 121(9): 3609-22.
22. Adams A, Warner K, Nör J-E. Salivary Gland Cancer Stem Cells. Oral Oncol 2013; 49(9): 845–53.
23. Zhou J, Hanna E, Roberts D, Weber R, Bell D. ALDH1 immunohistochemical expression and its significance in salivary adenoid cystic carcinoma. Journal of the Science and Specialties of Head and Neck 2013; 35( 4): 575–78.
24. Fujita S, Ikeda T. Cancer stem-like cells in adenoid cystic carcinoma of salivary glands: relationship with morphogenesis of histological variants. Journal of Oral Pathology & Medicine 2012; 41(3): 207–13.
25. Adams A, Warner K, Pearson A, Zhang Z, Kim H, Mochizuki D, et al. ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget 2015; 6(29): 26633-50.
26. Zhang L, Xia Y, Li L, Wang Y, Liu Y, Li C, et al. Cancer stem cell-like cells exist in mucoepidermoid carcinoma cell line MC3. Oncol Res 2012; 20(12):589-600.
27. Huang CF, Xu XR, Wu TF, Sun ZJ, Zhang WF. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis. J Oral pathol Med 2014;43(7): 492–498.
28. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, et al. Prognostic Value of Cancer Stem Cell Marker Aldehyde Dehydrogenase in Ovarian Cancer: A Meta-Analysis. Plos one 2013; 8 (11): e81050.
29. Qiu Y, Pu T, Li L , Cheng F, Lu C, Sun L, et al. The Expression of Aldehyde Dehydrogenase Family in Breast Cancer. Journal of Breast Cancer 2014; 17(1): 54-60.
30. Schwartz T, Stark A, Pang J, Awuah B, Kleer CG, Quayson S et al. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer 2013; 119(3):488-94.
31. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011; 10(9):1378-84.
32. Gonzalez A, Salas C, Provencio M, Orcajo N, Diez-Tascon C, Santin E, et al. The role of ALDH1 and CD133 expression as stem cell tumor marker in early-stage NSCLC. J Clin Oncol. 2015; 33(15): e13508.